Elevance Health, Inc. filings document formal disclosures for a health benefits and healthcare services company, including Form 8-K reports of quarterly and annual results, earnings guidance, benefit expense ratio updates, and Regulation FD communications. The filings also cover leadership changes, Carelon oversight, board appointments, committee assignments, and executive compensation matters reported through proxy materials.
Its regulatory documents include risk and operating disclosures tied to Health Benefits, Carelon, pharmacy and diversified healthcare services, provider contracting, product mix, government program funding, CMS Star Ratings, litigation, investigations, audits and professional-liability exposure. Recent 8-K disclosures also address CMS oversight of the company's Medicare Advantage-Prescription Drug plans.
Elevance Health, Inc. filed a shelf registration statement permitting it to offer senior and subordinated debt securities, preferred and common stock, depositary shares, warrants, rights, stock purchase contracts and stock purchase units. Offers and sales may occur from time to time after the registration statement becomes effective, on a continuous or delayed basis. Elevance may sell through underwriters, dealers or agents, or directly to purchasers; specific terms for each issue will appear in a prospectus supplement.
Unless a prospectus supplement specifies otherwise, net proceeds received from sales are intended for general corporate purposes, including debt repayment and possible acquisitions. Elevance served approximately 44.9 million medical members through affiliated health plans as of September 30, 2026.
Elevance Health, Inc. EVP & CFO Mark Kaye directly sold 10,584 common shares on October 22, 2026, across 13 reported transactions. No Rule 10b5-1 plan is reported.
Elevance Health, Inc. officer Mark B. Kaye reported a proposed sale of 10,584 common shares, with an aggregate market value of $4,658,378.26 and an approximate sale date of October 22, 2026. The shares are listed as restricted-stock and performance-share awards acquired from Elevance. Morgan Stanley Smith Barney LLC is listed as the broker.
Elevance Health, Inc. reported third-quarter 2026 shareholders’ net income of $1.365 billion, compared with $1.189 billion a year earlier, on total revenues of $51.429 billion versus $50.711 billion. Diluted shareholders’ earnings per share were $6.27, compared with $5.32.
For the first nine months of 2026, shareholders’ net income was $4.592 billion versus $5.115 billion, while net cash provided by operating activities was $7.512 billion versus $4.206 billion. Cash and cash equivalents were $10.348 billion as of September 30, 2026.
CMS informed Elevance on July 13, 2026, that it had completed the required steps related to a Medicare Advantage risk-adjustment notice, sanctions would not be imposed, and the enforcement process was closed. Elevance reported a related accrual of $593 million as of September 30, 2026. CarelonRx entered a new five-year agreement with CVS, effective January 1, 2027, through December 31, 2031, subject to certain early termination rights. The Audit Committee declared a fourth-quarter 2026 dividend of $1.72 per share, payable December 18 to shareholders of record December 4, 2026.
Elevance Health, Inc. reported third-quarter 2026 operating revenue of $50.4 billion, up 0.7% year over year, with diluted EPS of $6.27 and adjusted diluted EPS of $6.99. The company raised full-year 2026 guidance to at least $22.00 in diluted EPS, at least $29.00 in adjusted diluted EPS and at least $6.5 billion in operating cash flow.
Third-quarter shareholders’ net income rose 14.8% to $1.365 billion, while nine-month shareholders’ net income fell 10.2% to $4.592 billion. Health Benefits revenue increased 2.6% to $43.357 billion, but its operating gain fell 27.5% to $436 million; Carelon operating gain rose 17% to $0.9 billion. Medical membership was 44.882 million as of September 30, 2026, down 1.1% year over year. The company repurchased 0.8 million shares for $330 million and paid $373 million in quarterly dividends; it declared a fourth-quarter dividend of $1.72 per share, payable December 18, 2026, to shareholders of record December 4, 2026.
Elevance Health, Inc. (ELV) EVP & CFO Mark Kaye reported 4,161 shares withheld to pay tax liability in connection with vesting of previously granted restricted stock on October 2, 2026; the reported price was $386.43 per share. He also acquired 2,627 shares represented by performance-based restricted share units whose restrictions lapsed that day. No Rule 10b5-1 plan is reported.
Elevance Health, Inc. (ELV) reports that its officers plan to meet with investors and analysts and will reaffirm 2026 shareholders’ earnings guidance. The company continues to expect full-year 2026 earnings of at least $20.10 per diluted share, which includes approximately $6.90 per diluted share of net unfavorable items.
Excluding these net unfavorable items, Elevance Health continues to expect adjusted shareholders’ earnings of at least $27.00 per diluted share for 2026. The company is also reaffirming full-year 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points, consistent with prior expectations.
Elevance Health, Inc. executive Erin M. Wessling, EVP & Chief Legal Officer, reported two transactions in Elevance Health common stock. On September 3, 2026, 255 shares were disposed of at $414.78 per share, and on September 2, 2026, 94 shares were disposed of at $405.84 per share. Both transactions are identified as payment of tax liability by withholding stock incident to the vesting of previously granted restricted stock, and no Rule 10b5-1 trading plan is reported.
Elevance Health, Inc. (ELV) reported that EVP & Chief HR Officer Ryan R. Craig had 144 shares of common stock withheld on September 2, 2026 to pay tax liability associated with the vesting of previously granted restricted stock. The shares were valued at $405.84 per share, and Craig now holds 6,530 shares directly. No Rule 10b5-1 trading plan is reported for this transaction.
Elevance Health director Ramiro G Peru purchased 1,000 shares of common stock on 2026-07-17 at $366.05 per share. Following this open-market transaction, he directly owns 10,908 shares of Elevance Health, Inc. common stock.